How Regulatory Affairs Works With Clinical

Regulatory affairs and clinical operations work from the same protocol but answer to different clocks. Clinical is responsible for what actually happens at each site — enrollment, consent, data collection. Regulatory is responsible for keeping the government’s record of the study current and for reporting anything that changes the risk picture. The friction shows up exactly where those two clocks are supposed to sync and don’t.

In brief

Both functions work from the same protocol, but clinical owns its execution at sites — enrollment, informed consent, data collection, under 21 CFR Parts 50 and 56 — while regulatory owns keeping FDA’s record of the study current: protocol amendments under 21 CFR § 312.30, safety reporting under § 312.32.
A change at the site level — a protocol deviation, an unexpected adverse event, a change to how consent is obtained — only becomes a regulatory problem once someone tells regulatory affairs about it. The gap between “clinical knows” and “regulatory knows” is where most of the real risk in this relationship lives.
Regulatory doesn’t run the trial and shouldn’t try to; clinical doesn’t file with FDA and shouldn’t try to. The job on both sides is translation, not duplication.
The healthiest version of this relationship runs on a standing habit, not just a form: clinical flags anything unusual early enough that regulatory can assess reportability before a deadline is already close.

Where the division of labor actually falls

Regulatory affairs is accountable for what FDA sees: keeping the IND or IDE current, filing protocol amendments under 21 CFR § 312.30 when the design changes, and tracking the safety-reporting clock under § 312.32 once a study is running. Clinical operations is accountable for what happens to a subject: executing informed consent, maintaining IRB approval and continuing review under 21 CFR Part 56, monitoring sites, and producing the raw data that eventually becomes a clinical study report. Neither function can do the other’s job well from the outside — regulatory doesn’t sit in on site visits, and clinical operations doesn’t track FDA’s reporting clocks day to day. The application that starts a study is regulatory’s document, but every assumption inside it — the dose, the population, the monitoring plan — is something clinical has to execute faithfully for the rest of the trial to mean anything.

Where it breaks

The failure mode here isn’t usually a disagreement about who should own something — it’s a delay in the handoff. A site reports an adverse event to the study team; someone has to recognize it might be reportable to FDA and route it to whoever manages the safety-reporting clock. Enrollment isn’t working as designed and the protocol needs to change; someone has to recognize that isn’t just an operational fix, it’s a regulatory submission. The relationship works when there’s a standing habit — a weekly touchpoint, a shared tracker, anything that doesn’t depend on someone remembering to escalate — rather than a policy that assumes the right person will always think to call. It’s the same shape of problem this site has already described between regulatory and quality: two functions sharing a factual record, with no single person who automatically sees the whole picture.

Where this goes wrong

Treating a protocol amendment as clinical’s decision alone

A change made for operational reasons at sites still has to be assessed for whether it needs to go to FDA before it’s implemented, not after.

Routing safety information too slowly

The reportability clock under 21 CFR § 312.32 starts when the sponsor first learns of a possibly reportable event, not when the write-up is finished — a handoff that waits for a full report burns days that don’t come back.

Assuming informed consent stays current on its own

When a protocol change affects what a subject was told, the consent form has to change with it — that’s a joint check, not something either function verifies alone.

None of this requires regulatory affairs to learn clinical operations, or the other way around. It requires both functions to agree, ahead of time, on what gets flagged and how fast — so the first time either side hears about a problem isn’t the day a deadline is already close.

Sources & further reading

21 CFR § 312.30 — Protocol Amendments ecfr.gov
21 CFR § 312.32 — IND Safety Reporting ecfr.gov
Regulatory Academy — How Regulatory Affairs Works With Quality regulatoryacademy.com
Regulatory Academy — How to Read an IND Application regulatoryacademy.com

This essay is provided for general educational purposes and reflects the regulatory landscape as of its publication date. It is not legal, regulatory, or career advice.